About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker NVS · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Oct 28, 2026PIQRAY
ALPELISIB
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA212526 ↗
Oct 15, 2026COSENTYX
SECUKINUMAB
NVS
Novartis Pharmaceuticals Corp
Biologic (BLA), supplement
Efficacy
BLA761349 ↗
Oct 15, 2026COSENTYX
SECUKINUMAB
NVS
Novartis Pharmaceuticals Corp
Biologic (BLA), supplement
Labeling
BLA125504 ↗
Oct 6, 2026RHAPSIDO
REMIBRUTINIB
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA218436 ↗
Sep 22, 2026SCEMBLIX
ASCIMINIB HYDROCHLORIDE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA215358 ↗
Sep 16, 2026ZORTRESS
EVEROLIMUS
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA021560 ↗
Aug 19, 2026LEQVIO
INCLISIRAN SODIUM
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA214012 ↗
Jul 31, 2026PLUVICTO
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA215833 ↗
Jul 29, 2026MYFORTIC
MYCOPHENOLATE SODIUM
NVS
Novartis
New drug (NDA), supplement
REMS
NDA050791 ↗
Jul 29, 2026MYFORTIC
MYCOPHENOLATE SODIUM
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA050791 ↗
Jul 16, 2026FABHALTA
IPTACOPAN HYDROCHLORIDE
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA218276 ↗
Jul 15, 2026TEGRETOL XR
CARBAMAZEPINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA020234 ↗
Letter or label ↗
Jul 15, 2026TEGRETOL
CARBAMAZEPINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA018927 ↗
Letter or label ↗
Jul 15, 2026TEGRETOL
CARBAMAZEPINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA016608 ↗
Letter or label ↗
Jul 13, 2026GLEEVEC
IMATINIB MESYLATE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA021588 ↗
Jul 1, 2026KISQALI FEMARA CO-PACK (COPACKAGED)
LETROZOLE; RIBOCICLIB SUCCINATE
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA209935 ↗
Jul 1, 2026KISQALI
RIBOCICLIB SUCCINATE
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA209092 ↗
Jun 30, 2026MAYZENT
SIPONIMOD
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA209884 ↗
Jun 1, 2026AFINITOR DISPERZ
EVEROLIMUS
NVS
Novartis Pharm
New drug (NDA), supplement
Labeling
NDA203985 ↗
Letter or label ↗
Jun 1, 2026AFINITOR
EVEROLIMUS
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA022334 ↗
Letter or label ↗
May 29, 2026SANDIMMUNE
CYCLOSPORINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA050574 ↗
Letter or label ↗
May 7, 2026MEKINIST
TRAMETINIB DIMETHYL SULFOXIDE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA204114 ↗
Apr 17, 2026COSENTYX
SECUKINUMAB
NVS
Novartis Pharmaceuticals Corp
Biologic (BLA), supplement
Labeling
BLA761349 ↗
Apr 17, 2026COSENTYX
SECUKINUMAB
NVS
Novartis Pharmaceuticals Corp
Biologic (BLA), supplement
Labeling
BLA761349 ↗
Apr 17, 2026COSENTYX
SECUKINUMAB
NVS
Novartis Pharmaceuticals Corp
Biologic (BLA), supplement
Efficacy
BLA125504 ↗
Apr 17, 2026COSENTYX
SECUKINUMAB
NVS
Novartis Pharmaceuticals Corp
Biologic (BLA), supplement
Efficacy
BLA125504 ↗
Apr 14, 2026SCEMBLIX
ASCIMINIB HYDROCHLORIDE
NVS
Novartis
New drug (NDA), supplement
Manufacturing (CMC)
NDA215358 ↗
Apr 7, 2026PLUVICTO
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA215833 ↗
Apr 1, 2026KESIMPTA
OFATUMUMAB
NVS
Novartis
Biologic (BLA), supplement
Labeling
BLA125326 ↗
Mar 26, 2026TAFINLAR
DABRAFENIB MESYLATE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA217514 ↗
Letter or label ↗
Mar 26, 2026MEKINIST
TRAMETINIB; TRAMETINIB DIMETHYL SULFOXIDE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA217513 ↗
Letter or label ↗
Mar 26, 2026MEKINIST
TRAMETINIB DIMETHYL SULFOXIDE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA204114 ↗
Letter or label ↗
Mar 26, 2026TAFINLAR
DABRAFENIB MESYLATE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA202806 ↗
Letter or label ↗
Mar 12, 2026COSENTYX
SECUKINUMAB
NVS
Novartis Pharmaceuticals Corp
Biologic (BLA), supplement
Labeling
BLA761349 ↗
Mar 12, 2026COSENTYX
SECUKINUMAB
NVS
Novartis Pharmaceuticals Corp
Biologic (BLA), supplement
Efficacy
BLA125504 ↗
Mar 6, 2026SANDIMMUNE
CYCLOSPORINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA050625 ↗
Mar 6, 2026SANDIMMUNE
CYCLOSPORINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA050574 ↗
Mar 6, 2026SANDIMMUNE
CYCLOSPORINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA050573 ↗
Feb 12, 2026LEQVIO
INCLISIRAN SODIUM
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA214012 ↗
Feb 12, 2026LEQVIO
INCLISIRAN SODIUM
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA214012 ↗
Jan 14, 2026GLEEVEC
IMATINIB MESYLATE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA021588 ↗
Nov 25, 2025SCEMBLIX
ASCIMINIB HYDROCHLORIDE
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA215358 ↗
Oct 20, 2025VANRAFIA
ATRASENTAN HYDROCHLORIDE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA219208 ↗
Oct 2, 2025SCEMBLIX
ASCIMINIB HYDROCHLORIDE
NVS
Novartis
New drug (NDA), supplement
Efficacy
NDA215358 ↗
Sep 30, 2025RHAPSIDO
REMIBRUTINIB
NVS
Novartis
New drug (NDA)
Type 1 - New Molecular Entity
NDA218436 ↗
Letter or label ↗
Sep 30, 2025TEGRETOL XR
CARBAMAZEPINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA020234 ↗
Letter or label ↗
Sep 30, 2025TEGRETOL
CARBAMAZEPINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA018927 ↗
Sep 30, 2025TEGRETOL
CARBAMAZEPINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA016608 ↗
Sep 23, 2025TRILEPTAL
OXCARBAZEPINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA021285 ↗
Sep 23, 2025TRILEPTAL
OXCARBAZEPINE
NVS
Novartis
New drug (NDA), supplement
Labeling
NDA021014 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:04 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates